País: Canadà
Idioma: anglès
Font: Health Canada
ENTECAVIR (ENTECAVIR MONOHYDRATE)
MINT PHARMACEUTICALS INC
J05AF10
ENTECAVIR
0.5MG
TABLET
ENTECAVIR (ENTECAVIR MONOHYDRATE) 0.5MG
ORAL
15G/50G
Prescription
NUCLEOSIDES AND NUCLEOTIDES
Active ingredient group (AIG) number: 0151648001; AHFS:
APPROVED
2019-02-21
PRODUCT MONOGRAPH Pr MINT-ENTECAVIR Entecavir Tablets Entecavir (as monohydrate) 0.5 mg USP Antiviral Mint Pharmaceuticals Inc. 6575 Davand Drive Mississauga, Ontario L5T 2M3 Control No.: 246118 Date of Revision: March 22, 2021 _Page 2 of 44 _ _ _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................ 3 SUMMARY PRODUCT INFORMATION ................................................................................. 3 INDICATIONS AND CLINICAL USE ....................................................................................... 3 CONTRAINDICATIONS............................................................................................................ 3 WARNINGS AND PRECAUTIONS ........................................................................................... 4 ADVERSE REACTIONS ............................................................................................................ 6 DRUG INTERACTIONS .......................................................................................................... 10 DOSAGE AND ADMINISTRATION ....................................................................................... 10 OVERDOSAGE ........................................................................................................................ 11 ACTION AND CLINICAL PHARMACOLOGY ...................................................................... 11 STORAGE AND STABILITY .................................................................................................. 18 DOSAGE FORMS, COMPOSITION AND PACKAGING ....................................................... 19 PART II: SCIENTIFIC INFORMATION ................................................................................. 20 PHARMACEUTICAL INFORMATION ................................................................................... 20 CLINICAL TRIALS .................................................................................................................. Llegiu el document complet